T. Rowe Price Associates, Inc. 13D and 13G filings for Vera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 12:19 pm Sale | 2025-09-30 | 13G | Vera Therapeutics, Inc. VERA | T. Rowe Price Associates, Inc. | 3,666,598 5.700% | -272,511 (-6.92%) | Filing |
| 2024-11-14 1:22 pm Purchase | 2024-09-30 | 13G | Vera Therapeutics, Inc. VERA | T. Rowe Price Associates, Inc. | 3,939,109 7.200% | 3,939,109 (New Position) | Filing |